A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
NCT00936988
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperparathyroidism, Primary
Interventions
DRUG:
cinacalcet
Sponsor
Amgen